Yahoo Αναζήτηση Διαδυκτίου

Αποτελέσματα Αναζήτησης

1. pubmed.ncbi.nlm.nih.gov › 21142856The SATURN trial: the value of maintenance erlotinib in ... -...

   pubmed.ncbi.nlm.nih.gov › 21142856

   The Sequential Tarceva in Unresectable NSCLC (SATURN) study investigated the use of maintenance erlotinib following the completion of first-line chemotherapy. It demonstrated a significant improvement in overall survival from 11.1 months in the placebo group to 12.3 months in patients receiving maintenance erlotinib, with the important caveat ...

   • PMC

     The Sequential Tarceva in Unresectable NSCLC (SATURN) trial...

2. www.annalsofoncology.org › article › S0923-7534(19)34387-XSurvival benefit with erlotinib maintenance therapy in patients...

   www.annalsofoncology.org › article › S0923-7534(19)34387-X

   15 Οκτ 2010 · In the phase III SequentiAl Tarceva® in UnResectable NSCLC (SATURN; BO18192) study, maintenance therapy with erlotinib significantly increased progression-free and overall survival (PFS and OS) versus placebo in both the overall intention-to-treat (ITT) population and in patients with EGFR immunohistochemistry (IHC)-positive tumours . These ...

3. link.springer.com › article › 10Erlotinib in routine clinical practice for first-line maintenance...

   link.springer.com › article › 10

   • Αποθηκευμένο αντίγραφο

   23 Απρ 2018 · The controlled phase III trial SATURN demonstrated that maintenance therapy with erlotinib after the first-line platinum-based chemotherapy prolonged progression-free survival (PFS) and overall survival (OS) of non-small cell lung cancer (NSCLC) patients with advanced, non-progressive disease.

4. ascopubs.org › doi › 10Prospective Molecular Marker Analyses of EGFR and KRAS From a ...

   ascopubs.org › doi › 10

   3 Οκτ 2011 · The phase III, randomized, placebo-controlled Sequential Tarceva in Unresectable NSCLC (SATURN; BO18192) study evaluated maintenance erlotinib in patients with nonprogressive disease following first-line platinum-doublet chemotherapy.

5. www.tandfonline.com › doi › fullThe SATURN Trial: The Value of Maintenance Erlotinib in Patients...

   www.tandfonline.com › doi › full

   13 Δεκ 2010 · The Sequential Tarceva in Unresectable NSCLC (SATURN) study investigated the use of maintenance erlotinib following the completion of first-line chemotherapy. It demonstrated a significant improvement in overall survival from 11.1 months in the placebo group to 12.3 months in patients receiving maintenance erlotinib, with the important caveat ...

6. www.ncbi.nlm.nih.gov › pmc › articlesThe SATURN trial: the value of maintenance erlotinib in patients...

   www.ncbi.nlm.nih.gov › pmc › articles

   The Sequential Tarceva in Unresectable NSCLC (SATURN) trial was designed to investigate the effectiveness of maintenance erlotinib treatment until the time of progression, with the goal of prolonging overall survival and delaying disease progression .

7. www.ncbi.nlm.nih.gov › pmc › articlesEfficacy and safety of erlotinib in the treatment of metastatic...

   www.ncbi.nlm.nih.gov › pmc › articles

   20 Δεκ 2010 · Recently, Cappuzzo et al 50 presented data from the Sequential Tarceva in Unresectable NSCLC (SATURN) trial a double-blind, randomized, phase III study of maintenance erlotinib vs placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. The final results of the study found that the median OS ...